Cargando…
Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1)
OBJECTIVES: The emergence of SARS-CoV-2 variants raised questions about the extent to which vaccines designed in 2020 have remained effective. We aimed to assess whether vaccine status was associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients. METHODS: We conducted an...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798780/ https://www.ncbi.nlm.nih.gov/pubmed/36587737 http://dx.doi.org/10.1016/j.cmi.2022.12.020 |
_version_ | 1784860977212162048 |
---|---|
author | Beraud, Guillaume Bouetard, Laura Civljak, Rok Michon, Jocelyn Tulek, Necla Lejeune, Sophie Millot, Romain Garchet-Beaudron, Aurélie Lefebvre, Maeva Velikov, Petar Festou, Benjamin Abgrall, Sophie Lizatovic, Ivan K. Baldolli, Aurélie Esmer, Huseyin Blanchi, Sophie Froidevaux, Gabrielle Kapincheva, Nikol Faucher, Jean-François Duvnjak, Mario Afşar, Elçin Švitek, Luka Yarimoglu, Saliha Yarimoglu, Rafet Janssen, Cécile Epaulard, Olivier |
author_facet | Beraud, Guillaume Bouetard, Laura Civljak, Rok Michon, Jocelyn Tulek, Necla Lejeune, Sophie Millot, Romain Garchet-Beaudron, Aurélie Lefebvre, Maeva Velikov, Petar Festou, Benjamin Abgrall, Sophie Lizatovic, Ivan K. Baldolli, Aurélie Esmer, Huseyin Blanchi, Sophie Froidevaux, Gabrielle Kapincheva, Nikol Faucher, Jean-François Duvnjak, Mario Afşar, Elçin Švitek, Luka Yarimoglu, Saliha Yarimoglu, Rafet Janssen, Cécile Epaulard, Olivier |
author_sort | Beraud, Guillaume |
collection | PubMed |
description | OBJECTIVES: The emergence of SARS-CoV-2 variants raised questions about the extent to which vaccines designed in 2020 have remained effective. We aimed to assess whether vaccine status was associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients. METHODS: We conducted an international, multi-centric, retrospective study in 14 centres (Bulgaria, Croatia, France, and Turkey). We collected data on patients hospitalized for ≥24 hours between 1 December 2021 and 3 March 2022 with PCR-confirmed infection at a time of exclusive Omicron circulation and hospitalization related or not related to the infection. Patients who had received prophylaxis by monoclonal antibodies were excluded. Patients were considered fully vaccinated if they had received at least two injections of either mRNA and/or ChAdOx1-S or one injection of Ad26.CoV2-S vaccines. RESULTS: Among 1215 patients (median age, 73.0 years; interquartile range, 57.0–84.0; 51.3% men), 746 (61.4%) were fully vaccinated. In multivariate analysis, being vaccinated was associated with lower 28-day mortality (Odds Ratio [95% Confidence Interval] (OR [95CI]) = 0.50 [0.32–0.77]), intensive care unit admission (OR [95CI] = 0.40 [0.26–0.62]), and oxygen requirement (OR [95CI] = 0.34 [0.25–0.46]), independent of age and comorbidities. When co-analysing these patients with Omicron infection with 948 patients with Delta infection from a study we recently conducted, Omicron infection was associated with lower 28-day mortality (OR [95CI] = 0.53 [0.37–0.76]), intensive care unit admission (OR [95CI] = 0.19 [0.12–0.28]), and oxygen requirements (OR [95CI] = 0.50 [0.38–0.67]), independent of age, comorbidities, and vaccination status. DISCUSSION: Originally designed vaccines have remained effective on the severity of Omicron SARS-CoV-2 infection. Omicron is associated with a lower risk of severe forms, independent of vaccination and patient characteristics. |
format | Online Article Text |
id | pubmed-9798780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97987802022-12-29 Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1) Beraud, Guillaume Bouetard, Laura Civljak, Rok Michon, Jocelyn Tulek, Necla Lejeune, Sophie Millot, Romain Garchet-Beaudron, Aurélie Lefebvre, Maeva Velikov, Petar Festou, Benjamin Abgrall, Sophie Lizatovic, Ivan K. Baldolli, Aurélie Esmer, Huseyin Blanchi, Sophie Froidevaux, Gabrielle Kapincheva, Nikol Faucher, Jean-François Duvnjak, Mario Afşar, Elçin Švitek, Luka Yarimoglu, Saliha Yarimoglu, Rafet Janssen, Cécile Epaulard, Olivier Clin Microbiol Infect Original Article OBJECTIVES: The emergence of SARS-CoV-2 variants raised questions about the extent to which vaccines designed in 2020 have remained effective. We aimed to assess whether vaccine status was associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients. METHODS: We conducted an international, multi-centric, retrospective study in 14 centres (Bulgaria, Croatia, France, and Turkey). We collected data on patients hospitalized for ≥24 hours between 1 December 2021 and 3 March 2022 with PCR-confirmed infection at a time of exclusive Omicron circulation and hospitalization related or not related to the infection. Patients who had received prophylaxis by monoclonal antibodies were excluded. Patients were considered fully vaccinated if they had received at least two injections of either mRNA and/or ChAdOx1-S or one injection of Ad26.CoV2-S vaccines. RESULTS: Among 1215 patients (median age, 73.0 years; interquartile range, 57.0–84.0; 51.3% men), 746 (61.4%) were fully vaccinated. In multivariate analysis, being vaccinated was associated with lower 28-day mortality (Odds Ratio [95% Confidence Interval] (OR [95CI]) = 0.50 [0.32–0.77]), intensive care unit admission (OR [95CI] = 0.40 [0.26–0.62]), and oxygen requirement (OR [95CI] = 0.34 [0.25–0.46]), independent of age and comorbidities. When co-analysing these patients with Omicron infection with 948 patients with Delta infection from a study we recently conducted, Omicron infection was associated with lower 28-day mortality (OR [95CI] = 0.53 [0.37–0.76]), intensive care unit admission (OR [95CI] = 0.19 [0.12–0.28]), and oxygen requirements (OR [95CI] = 0.50 [0.38–0.67]), independent of age, comorbidities, and vaccination status. DISCUSSION: Originally designed vaccines have remained effective on the severity of Omicron SARS-CoV-2 infection. Omicron is associated with a lower risk of severe forms, independent of vaccination and patient characteristics. The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2023-05 2022-12-29 /pmc/articles/PMC9798780/ /pubmed/36587737 http://dx.doi.org/10.1016/j.cmi.2022.12.020 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Beraud, Guillaume Bouetard, Laura Civljak, Rok Michon, Jocelyn Tulek, Necla Lejeune, Sophie Millot, Romain Garchet-Beaudron, Aurélie Lefebvre, Maeva Velikov, Petar Festou, Benjamin Abgrall, Sophie Lizatovic, Ivan K. Baldolli, Aurélie Esmer, Huseyin Blanchi, Sophie Froidevaux, Gabrielle Kapincheva, Nikol Faucher, Jean-François Duvnjak, Mario Afşar, Elçin Švitek, Luka Yarimoglu, Saliha Yarimoglu, Rafet Janssen, Cécile Epaulard, Olivier Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1) |
title | Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1) |
title_full | Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1) |
title_fullStr | Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1) |
title_full_unstemmed | Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1) |
title_short | Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1) |
title_sort | impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the omicron variant (b.1.1.529) of the sars-cov-2 (subvariant ba.1) |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798780/ https://www.ncbi.nlm.nih.gov/pubmed/36587737 http://dx.doi.org/10.1016/j.cmi.2022.12.020 |
work_keys_str_mv | AT beraudguillaume impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT bouetardlaura impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT civljakrok impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT michonjocelyn impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT tuleknecla impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT lejeunesophie impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT millotromain impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT garchetbeaudronaurelie impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT lefebvremaeva impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT velikovpetar impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT festoubenjamin impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT abgrallsophie impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT lizatovicivank impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT baldolliaurelie impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT esmerhuseyin impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT blanchisophie impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT froidevauxgabrielle impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT kapinchevanikol impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT faucherjeanfrancois impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT duvnjakmario impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT afsarelcin impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT svitekluka impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT yarimoglusaliha impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT yarimoglurafet impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT janssencecile impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT epaulardolivier impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 AT impactofvaccinationonthepresenceandseverityofsymptomsinhospitalizedpatientswithaninfectionoftheomicronvariantb11529ofthesarscov2subvariantba1 |